European Society for Medical Oncology (ESMO) 2023 Congress October 23, 2023 at 10:30 AM EDT Supporting Materials Li et atl ESMO 2023 Poster BDC-1001 Phase 1 Data 1.3 MB Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
